



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65078

**Title:** First-line Pazopanib in Patients with Advanced Non-Clear Cell Renal Carcinoma:  
an Italian Case Series

**Reviewer's code:** 05223955

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor, Surgeon, Surgical Oncologist

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-02-27

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-04-07 04:14

**Reviewer performed review:** 2021-04-07 04:34

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

There is no real clinical hesitation in the Asia-Oceania region to use pazopanib in nccRCC patients, but this difference in perception should be corrected again using the EAU and AUA guideline recommendations as an example. Please revise the text in Introduction section.